Magnetic resonance imaging of the prostate at 1.5T vs. 3.0T: A comparative analysis of day-to-day practice.
BAUS ePoster online library. Bass E. 06/21/21; 318991; p1-3
Disclosure(s): Nothing to declare
Mr. Edward Bass
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction:
Multiparametric MRI (mpMRI) has seen widespread adoption. There is unanimous agreement that a magnet strength of ≥1.5T is essential for accurate prostate imaging due to the speed and imaging resolution improvements. Many now recommend 3.0T as the optimal platform. As part of a prostate cancer diagnostics service transformation programme, we investigated to what extent the adoption of 3.0T mpMRI improved clinically significant prostate cancer (csPCa) detection.
Methods:
We performed a sensitivity analysis (sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and receiver operating curve characteristic (AUC)) of 1.5T and 3.0T mpMRI for csPCa (G3+4), using a positivity threshold of ≥PIRADS 4.
Results:
Between 11/2016 and 02/2020, 265 and 120 consecutive men underwent 1.5 or 3.0T mpMRIs (T2, DWI, DCE) respectively followed by a template mapping biopsy. Median PSA, age, prostate volume and PSA densities were 6.0 ng/mL [IQR 4.6-8.7], 64 years [IQR 59-70], 51mL [IQR 35-72] and 0.11ng/mL/mL [IQR 0.08-0.17]. There were no significant differences in these parameters between the two groups (p>0.05). The sensitivity, specificity, PPV, NPV and AUC for 1.5T mpMRI detecting G3+4 cancer was 82.6 [72.9-89.0], 65.3 [57.4-72.3], 53.8 [48.2-59.3], 88.5 [69.9-80.5] and 0.79 [0.73-0.84]. For 3.0T mpMRI, the same parameters were 75.9 [62.8-86.1], 53.2 [40.1-66.0], 60.3 [52.9-67.3], 70.2 [58.5-79.7] and 0.67 [0.59-0.76].
Conclusions:
This analysis suggests that 1.5T mpMRI has greater utility in detecting csPCa than 3.0T mpMRI. This may reflect the subtle differences in image attributes and learning curve in reporting them. A repeat analysis is planned for last quarter 2021.
Multiparametric MRI (mpMRI) has seen widespread adoption. There is unanimous agreement that a magnet strength of ≥1.5T is essential for accurate prostate imaging due to the speed and imaging resolution improvements. Many now recommend 3.0T as the optimal platform. As part of a prostate cancer diagnostics service transformation programme, we investigated to what extent the adoption of 3.0T mpMRI improved clinically significant prostate cancer (csPCa) detection.
Methods:
We performed a sensitivity analysis (sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and receiver operating curve characteristic (AUC)) of 1.5T and 3.0T mpMRI for csPCa (G3+4), using a positivity threshold of ≥PIRADS 4.
Results:
Between 11/2016 and 02/2020, 265 and 120 consecutive men underwent 1.5 or 3.0T mpMRIs (T2, DWI, DCE) respectively followed by a template mapping biopsy. Median PSA, age, prostate volume and PSA densities were 6.0 ng/mL [IQR 4.6-8.7], 64 years [IQR 59-70], 51mL [IQR 35-72] and 0.11ng/mL/mL [IQR 0.08-0.17]. There were no significant differences in these parameters between the two groups (p>0.05). The sensitivity, specificity, PPV, NPV and AUC for 1.5T mpMRI detecting G3+4 cancer was 82.6 [72.9-89.0], 65.3 [57.4-72.3], 53.8 [48.2-59.3], 88.5 [69.9-80.5] and 0.79 [0.73-0.84]. For 3.0T mpMRI, the same parameters were 75.9 [62.8-86.1], 53.2 [40.1-66.0], 60.3 [52.9-67.3], 70.2 [58.5-79.7] and 0.67 [0.59-0.76].
Conclusions:
This analysis suggests that 1.5T mpMRI has greater utility in detecting csPCa than 3.0T mpMRI. This may reflect the subtle differences in image attributes and learning curve in reporting them. A repeat analysis is planned for last quarter 2021.
Introduction:
Multiparametric MRI (mpMRI) has seen widespread adoption. There is unanimous agreement that a magnet strength of ≥1.5T is essential for accurate prostate imaging due to the speed and imaging resolution improvements. Many now recommend 3.0T as the optimal platform. As part of a prostate cancer diagnostics service transformation programme, we investigated to what extent the adoption of 3.0T mpMRI improved clinically significant prostate cancer (csPCa) detection.
Methods:
We performed a sensitivity analysis (sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and receiver operating curve characteristic (AUC)) of 1.5T and 3.0T mpMRI for csPCa (G3+4), using a positivity threshold of ≥PIRADS 4.
Results:
Between 11/2016 and 02/2020, 265 and 120 consecutive men underwent 1.5 or 3.0T mpMRIs (T2, DWI, DCE) respectively followed by a template mapping biopsy. Median PSA, age, prostate volume and PSA densities were 6.0 ng/mL [IQR 4.6-8.7], 64 years [IQR 59-70], 51mL [IQR 35-72] and 0.11ng/mL/mL [IQR 0.08-0.17]. There were no significant differences in these parameters between the two groups (p>0.05). The sensitivity, specificity, PPV, NPV and AUC for 1.5T mpMRI detecting G3+4 cancer was 82.6 [72.9-89.0], 65.3 [57.4-72.3], 53.8 [48.2-59.3], 88.5 [69.9-80.5] and 0.79 [0.73-0.84]. For 3.0T mpMRI, the same parameters were 75.9 [62.8-86.1], 53.2 [40.1-66.0], 60.3 [52.9-67.3], 70.2 [58.5-79.7] and 0.67 [0.59-0.76].
Conclusions:
This analysis suggests that 1.5T mpMRI has greater utility in detecting csPCa than 3.0T mpMRI. This may reflect the subtle differences in image attributes and learning curve in reporting them. A repeat analysis is planned for last quarter 2021.
Multiparametric MRI (mpMRI) has seen widespread adoption. There is unanimous agreement that a magnet strength of ≥1.5T is essential for accurate prostate imaging due to the speed and imaging resolution improvements. Many now recommend 3.0T as the optimal platform. As part of a prostate cancer diagnostics service transformation programme, we investigated to what extent the adoption of 3.0T mpMRI improved clinically significant prostate cancer (csPCa) detection.
Methods:
We performed a sensitivity analysis (sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and receiver operating curve characteristic (AUC)) of 1.5T and 3.0T mpMRI for csPCa (G3+4), using a positivity threshold of ≥PIRADS 4.
Results:
Between 11/2016 and 02/2020, 265 and 120 consecutive men underwent 1.5 or 3.0T mpMRIs (T2, DWI, DCE) respectively followed by a template mapping biopsy. Median PSA, age, prostate volume and PSA densities were 6.0 ng/mL [IQR 4.6-8.7], 64 years [IQR 59-70], 51mL [IQR 35-72] and 0.11ng/mL/mL [IQR 0.08-0.17]. There were no significant differences in these parameters between the two groups (p>0.05). The sensitivity, specificity, PPV, NPV and AUC for 1.5T mpMRI detecting G3+4 cancer was 82.6 [72.9-89.0], 65.3 [57.4-72.3], 53.8 [48.2-59.3], 88.5 [69.9-80.5] and 0.79 [0.73-0.84]. For 3.0T mpMRI, the same parameters were 75.9 [62.8-86.1], 53.2 [40.1-66.0], 60.3 [52.9-67.3], 70.2 [58.5-79.7] and 0.67 [0.59-0.76].
Conclusions:
This analysis suggests that 1.5T mpMRI has greater utility in detecting csPCa than 3.0T mpMRI. This may reflect the subtle differences in image attributes and learning curve in reporting them. A repeat analysis is planned for last quarter 2021.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}